NEW YORK (GenomeWeb News) – The New York Genome Center has made a number of new hires.
Toby Bloom is the center's deputy scientific director of informatics. She joins the NYGC from the Broad Institute, where she was director of informatics for the Genome Sequencing Center.
Liying Zhang is interim director of the NYGC's CLIA-certified laboratory. Zhang is currently the director of the diagnostic molecular genetics laboratory at Memorial Sloan-Kettering and has a certificate of qualification from New York in molecular oncology and in molecular genetics.
Michelle Lamendola-Essel, who is also certified by New York, has been hired as senior clinical laboratory technician and will be responsible for running the CLIA lab on a day-to-day basis. Previously, she was lead molecular scientist at Enzo Biochem, and has held positions at Acupath Laboratories.
Atossa Genetics has named Michael Kalnoski its medical director, a newly created position. Kalnoski was previously a medical director and consultant at companies and institutions, including the Puget Sound Institute of Pathology, Hematologics, and Quest Diagnostics.
Cepheid said this week that Humberto Reyes, the firm’s former executive VP and chief operating officer, will transition out of the company, effective July 16.
Exosome Diagnostics has appointed Joseph Slattery to its board of directors. Slattery is CFO and executive VP of Baxano Surgical. Prior to Baxano, Slattery was CFO and senior VP of the molecular diagnostics firm Digene, now part of Qiagen.
The Federation of American Societies for Experimental Biology said this week that Margaret Offermann has stepped into her new role as FASEB president. She succeeds outgoing President Judith Bond.
Offermann is a medical oncologist and researcher, a managing partner at the consulting firm the Salutramed Group, and she formerly was deputy national VP for research at the American Cancer Society.
FASEB also said that Joseph Haywood is the new president-elect (he will succeed Offermann), and that Peter Rubenstein is president for science policy.
The cloud-based genomics data management company DNAnexus has appointed Ken Kershner to be its VP of engineering.
Kershner, who has built software engineering teams at Silicon Graphics and TiVo, will be responsible for heading the company’s development and product quality teams and will oversee the firm’s technology architecture. He most recently was VP of engineering and operations at DNAnexus.
The Texas Biomedical Research Institute has named Ruth Ruprecht, a professor of medicine at Harvard Medical School and the Dana-Farber Cancer Institute in Boston, and director of its AIDS Research Program in the Department of Virology and Immunology.
Ruprecht runs a multi-institutional, international AIDS research program, and her expertise is in vaccine development.
She has been a consultant for the World Health Organization and the China Comprehensive International Program for Research on AIDS and she serves on several scientific advisory boards, including the National Cancer Institute’s Vaccine Branch and the China Centers for Disease Control.
She is scheduled to take on the new post at Texas Biomed sometime in August.
Becton Dickinson has appointed Christopher Reidy to be company CFO and executive VP of administration, effective July 15.
Reidy will be responsible for executive management and oversight of BD's global financial operations and shared services and for oversight of IT. He formerly was corporate VP and CFO for six years at ADP; CFO at NBA Properties; a VP and division CFO at AT&T; and audit partner at Deloitte and Touche.
Naftali Kaminski has joined the Yale School of Medicine faculty as a professor of medicine and as chief of the section of Pulmonary, Critical Care and Sleep Medicine, Yale said last week.
Kaminski joins Yale from the University of Pittsburgh School of Medicine, where he was endowed chair for pulmonary research and a tenured professor of medicine, pathology, and computational biology and human genetics.
His primary research interests involve applying genomic approaches to elucidate basic mechanisms to improve diagnosis and treatment of idiopathic pulmonary fibrosis, a chronic lung disease.
David Wellis has been named CEO of the San Diego Blood Bank. Wellis was previously president of BioAlta, president and CEO of GenVault, and in charge of product marketing at Illumina.
He replaces outgoing CEO Ramona Walker, who is retiring.
Jonathan Lord has been named to Vigilant Biosciences' board of directors. Lord was previously CEO at Navigenics, which Life Technologies acquired a year ago. He currently serves as the chair of the board of directors of Dexcom, director at Stericycle, and is on the advisory board of Serco, Anthello Health, and Third Rock Ventures.
Additionally, he is chief operating officer of the University of Miami's Miller School of Medicine and a professor of pathology.
Iain Miller has established Healthcare Strategies Group, a London-based organization that provides strategic advisory services to life sciences tools firms and pharmaceutical companies.
Miller is involved in several international policy initiatives, including The European Personalized Medicine association, where he serves as a board member. Previously, Miller worked at GE Healthcare as the global head of personalized healthcare strategy and partnerships. While at BioMérieux, Miller was senior director of oncology strategy and theranostics, and led strategy and business development activities within the company's personalized medicine business unit.
Promoted? Changing jobs? GenomeWeb wants to know. [email protected] to appear in People In The News, a weekly roundup of industry comings and goings.